The efficacy of switching basal–bolus insulin therapy to basal insulin-supported oral therapy with a glinide and an α-glucosidase inhibitor in patients with type 2 diabetes depends on insulin secretory capacity, but not on blood glucose profiles and insulin dosages prior to the switching-Reference-Cited by-同舟云学术

The efficacy of switching basal–bolus insulin therapy to basal insulin-supported oral therapy with a glinide and an α-glucosidase inhibitor in patients with type 2 diabetes depends on insulin secretory capacity, but not on blood glucose profiles and insulin dosages prior to the switching

Published:2023-09-04 Issue:1 Volume:15 Page:99-108
ISSN:2190-1678
Container-title:Diabetology International
language:en
Short-container-title:Diabetol Int

Author:

Ando Toshihito,Kondo Masaki^ORCID,Asada-Yamada Yuriko,Kawai Miyuka,Asano-Hayami Emi,Hayami Tomohide,Motegi Mikio,Ejima Yohei,Nagao Eriko,Kasagi Rina,Nakai-Shimoda Hiromi,Asano Saeko,Kato Makoto,Yamada Yuichiro,Yura-Miura Emiri,Ishikawa Takahiro,Sugiura-Roth Yukako,Kojima Chika,Naito Ena,Himeno Tatsuhito,Tsunekawa Shin,Kato Yoshiro,Nakamura Jiro,Kamiya Hideki

Funder

Kissei

Publisher

Springer Science and Business Media LLC

Subject

Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://link.springer.com/content/pdf/10.1007/s13340-023-00651-z.pdf

Reference40 articles.

1. Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan B, et al. IDF Diabetes Atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022;183:109109. https://doi.org/10.1016/j.diabres.2021.109119.

2. Takeshita Y, Takamura T, Kita Y, Takazakura A, Kato K, Isobe Y, et al. Sitagliptin versus mitiglinide switched from mealtime dosing of a rapid-acting insulin analog in patients with type 2 diabetes: a randomized, parallel-group study. BMJ Open Diabetes Res Care. 2015. https://doi.org/10.1136/bmjdrc-2015-000122.

3. Tsukube S, Ikeda Y, Kadowaki T, Odawara M. Improved treatment satisfaction and self-reported health status after introduction of basal-supported oral therapy using insulin glargine in patients with type 2 diabetes: sub-analysis of ALOHA2 study. Diabetes Ther. 2015. https://doi.org/10.1007/s13300-015-0111-5.

4. Li H. Revisiting the strategies for the pharmacological management of type 2 diabetes—from glycemic control, organ protection, safety to weight reduction. J Diabetes Investig. 2022;13(1):3–5. https://doi.org/10.1111/jdi.13726.

5. Danne T, Bluhmki T, Seufert J, Kaltheuner M, Rathmann W, Beyersmann J, et al. Treatment intensification using long-acting insulin -predictors of future basal insulin supported oral therapy in the DIVE registry. BMC Endocr Disord. 2015;15:54. https://doi.org/10.1186/s12902-015-0051-0.